{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T19:51:37Z","timestamp":1792353097395,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Amphotericin B is an antifungal agent used to treat serious fungal infections mainly in critically ill patients. Despite its adverse effects including renal toxicity and electrolyte imbalances, amphotericin B remains one of the best choices for antifungal treatment. Information from animal studies has provided a strong scientific basis for the use of pentoxifylline as lowering nephroprotective agent. The present study was designed to evaluate the efficacy of pentoxifylline in preventing renal toxicity and electrolytes imbalances induced by amphotericin B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This study was conducted as a randomized controlled trial on 44 patients admitted to Sayyedoshohada Hospital, Isfahan, Iran, from October 2016 to August 2018. Patients were assigned to one of the two groups: Pentoxifylline, 400 mg twice a day, or matching placebo, from the 1\n                      <jats:sup>st<\/jats:sup>\n                      day of amphotericin B therapy till minimum of 7 days. All patients' information including lab data (serum and urine levels of Mg, Na, and K, serum creatinine level, blood urea nitrogen [BUN] and urinary creatinine excretion) were gathered at the time of drug initiation and during the study period. The results were analyzed by SPSS v. 20 software and Repeated measures test was used to assess the differences between groups\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>This study did not show any significant differences between the two groups in terms of all the assessed variables, including serum and urinary levels of electrolytes, and creatinine, as well as the number of cases presented acute kidney injury during the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Despite the positive effects of pentoxifylline in preventing renal complications in previous studies, this study could not show a definitive result in salt wasting or renal damage induced by amphotericin B. So, Designing robust studies with more included samples would be valuable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_20_98","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T09:49:13Z","timestamp":1602150553000},"page":"135-139","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Pentoxifylline in Prevention of Amphotericin B-induced Nephrotoxicity and Electrolyte Abnormalities"],"prefix":"10.4103","volume":"9","author":[{"given":"Mahsa","family":"Panahi-Shokouh","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Moghaddas","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirinsadat","family":"Badri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeedeh","family":"Jabalameli","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Momenzadeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valiollah","family":"Mehrzad","sequence":"additional","affiliation":[{"name":"Department of Oncology\/Hematology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Ashrafi","sequence":"additional","affiliation":[{"name":"Department of Oncology\/Hematology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"R1-20250523","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/joc.2000.12.6.463","article-title":"Amphotericin B-induced nephrotoxicity: A review","volume":"12","author":"Fanos","year":"2000","journal-title":"J Chemother"},{"key":"R2-20250523","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: Side effects and toxicity","volume":"26","author":"Laniado-Labor\u00edn","year":"2009","journal-title":"Rev Iberoam Micol"},{"key":"R3-20250523","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/B978-0-08-046884-6.00818-6","article-title":"Amphotericin B-induced nephrotoxicity","volume":"7","author":"Ulozas","year":"2010","journal-title":"Compr Toxicol"},{"key":"R4-20250523","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev Infect Dis"},{"key":"R5-20250523","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0002-9343(01)00928-7","article-title":"The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy","volume":"111","author":"Harbarth","year":"2001","journal-title":"Am J Med"},{"key":"R6-20250523","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00228-013-1472-1","article-title":"Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity","volume":"69","author":"Karimzadeh","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-20250523","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14740338.2012.721775","article-title":"Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?","volume":"11","author":"Karimzadeh","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R8-20250523","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0190-9622(94)70069-9","article-title":"Pentoxifylline","volume":"30","author":"Samlaska","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"R9-20250523","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/SHK.0b013e3181cdc3e2","article-title":"Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways","volume":"34","author":"Kreth","year":"2010","journal-title":"Shock"},{"key":"R10-20250523","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/intimm\/dxg079","article-title":"Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity","volume":"15","author":"Heystek","year":"2003","journal-title":"Int Immunol"},{"key":"R11-20250523","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00228-012-1452-x","article-title":"A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity","volume":"69","author":"Nasiri-Toosi","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-20250523","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0008-8749(91)90276-H","article-title":"Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes","volume":"135","author":"Rao","year":"1991","journal-title":"Cell Immunol"},{"key":"R13-20250523","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-5728(95)00176-X","article-title":"Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis","volume":"64","author":"Rieckmann","year":"1996","journal-title":"J Neuroimmunol"},{"key":"R14-20250523","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/ndt\/15.10.1535","article-title":"Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts","volume":"15","author":"Strutz","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R15-20250523","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/00007890-199005000-00007","article-title":"Pentoxifylline in the isolated perfused rat kidney","volume":"49","author":"Berens","year":"1990","journal-title":"Transplantation"},{"key":"R16-20250523","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/AAC.36.2.408","article-title":"Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro","volume":"36","author":"Sullivan","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20250523","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1046\/j.1523-1755.2001.00948.x","article-title":"Correlates of acute renal failure in patients receiving parenteral amphotericin B","volume":"60","author":"Bates","year":"2001","journal-title":"Kidney Int"},{"key":"R18-20250523","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1681\/ASN.V2198","article-title":"Chronic amphotericin B nephrotoxicity in the rat: Protective effect of calcium channel blockade","volume":"2","author":"Tolins","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"R19-20250523","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00228-014-1642-9","article-title":"N-acetyl cysteine in prevention of amphotericin-induced electrolytes imbalances: A randomized, double-blinded, placebo-controlled, clinical trial","volume":"70","author":"Karimzadeh","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"R20-20250523","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R21-20250523","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"R22-20250523","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1440-1797.2004.00267.x","article-title":"Pentoxifylline: A potential therapy for chronic kidney disease","volume":"9","author":"Lin","year":"2004","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"R23-20250523","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1726-4901(09)70228-X","article-title":"The renoprotective potential of pentoxifylline in chronic kidney disease","volume":"68","author":"Lin","year":"2005","journal-title":"J Chin Med Assoc"},{"issue":"8","key":"R24-20250523","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/sj.ki.5000302","article-title":"Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemo-attractant protein-1 in patients with proteinuric primary glomerular diseases","volume":"69","author":"Chen","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"R25-20250523","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/infdis\/162.1.211","article-title":"Enhancement of the treatment of experimental candidiasis with vascular decongestants","volume":"162","author":"Luke","year":"1990","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"R26-20250523","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/AAC.34.2.241","article-title":"Pentoxifylline in amphotericin B toxicity rat model","volume":"34","author":"Wasan","year":"1990","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"R27-20250523","first-page":"2382","article-title":"Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis","volume":"30","author":"Galindo-Rodr\u00edguez","year":"2003","journal-title":"J Rheumatol"},{"key":"R28-20250523","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40261-013-0057-1","article-title":"Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: A 6-month placebo-controlled trial","volume":"33","author":"Badri","year":"2013","journal-title":"Clin Drug Investig"},{"key":"R29-20250523","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/341662","article-title":"Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: Animal experiments and clinical study","volume":"186","author":"Mayer","year":"2002","journal-title":"J Infect Dis"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.JRPP_20_98","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:47Z","timestamp":1786735667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.JRPP_20_98"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_20_98","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"2020-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}